- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04257461
A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma (BALLAD)
BALLAD BELGIUM: A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The utility of adjuvant chemotherapy in the management of Small Bowel Adenocarcinoma (SBA) remains unproven and awaits the results of a large, global, prospective, phase III, randomised, controlled trial. Across the 830 million population of North America and Europe, there are approximately 3,000 patients with R0 resected and potentially cured SBA every year who would be potentially eligible for such an adjuvant chemotherapy trial.
Given the absence of good-quality and evidence-based data, it has been agreed that a trial considering adjuvant chemotherapy versus no chemotherapy was appropriate for patients with stage I-IV SBA in whom the oncologist and patient feel that the benefit of adjuvant chemotherapy is uncertain. For those patients with stage I-IV SBA who, with their oncologists, feel that the potential benefit of adjuvant chemotherapy is certain (and hence are not willing to accept randomisation to the 'no chemotherapy' arm), a randomisation between single agent fluoropyrimidine versus doublet fluoropyrimidine and oxaliplatin chemotherapy will be offered. Tumour stage will be used as a stratification factor. Those patients who do not consent to be randomised will be offered registration to allow collection of demographic, clinicopathological, epidemiological and survival data, thereby making optimal use of the rare patient population available. In addition, archival Formalin Fixed Paraffin Embedded (FFPE) tissue and contemporaneous venous blood samples will be collected from every registered patient to allow molecular profiling and future translational research. A questionnaire about underlying risk factors (e.g. Crohn's disease, coeliac disease, Lynch syndrome etc) will be completed along with the other collected data on all registered patients.
The trial hypotheses are that:
- Adjuvant chemotherapy results in an improved outcome (DFS and OS) over observation alone after potentially curative R0 surgery for stage I, II, III and IV SBA
- Adjuvant fluoropyrimidine and oxaliplatin chemotherapy results in an improved outcome (DFS and OS) over fluropyrimidine alone after potentially curative R0 surgery for stage I, II, III and IV SBA.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Ine De Bruyne
- Phone Number: 0032 478 81 04 27
- Email: i.debruyne@bgdo.org
Study Contact Backup
- Name: Micheline Stempin
- Phone Number: 0032 474 07 45 84
- Email: clinicaltrials@bgdo.org
Study Locations
-
-
-
Antwerp, Belgium, 2650
- Active, not recruiting
- UZ Antwerpen
-
Brussels, Belgium, 1070
- Active, not recruiting
- ULB Erasme
-
Brussels, Belgium, 1200
- Recruiting
- Cliniques Universitaires Saint-Luc UCL
-
Contact:
- Marie Ferrier
-
Principal Investigator:
- Marc Van den Eynde, Prof
-
Liège, Belgium, 4000
- Not yet recruiting
- CHU Liege
-
Contact:
- Maude Piron
-
Principal Investigator:
- Catherine Loly, Dr
-
Liège, Belgium, 4000
- Active, not recruiting
- CHC MontLegia
-
-
Antwerpen
-
Turnhout, Antwerpen, Belgium, 2300
- Active, not recruiting
- Az Turnhout
-
-
Oost-Vlaanderen
-
Aalst, Oost-Vlaanderen, Belgium, 9300
- Not yet recruiting
- Onze-Lieve-vrouw Ziekenhuis Aalst
-
Contact:
- Kristel Van Varenbergh
-
Principal Investigator:
- Koen Hendrickx, Dr
-
Gent, Oost-Vlaanderen, Belgium, 9000
- Active, not recruiting
- AZ St-Lucas
-
-
West-Vlaanderen
-
Roeselare, West-Vlaanderen, Belgium, 8800
- Active, not recruiting
- AZ Delta
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- R0 resected stage I, II or III SBA
- No evidence of residual or metastatic disease at laparotomy and on CT/MRI imaging of chest, abdomen and pelvis.
- Patients must be registered and randomised within 12 weeks of surgery and commence chemotherapy within 14 weeks of surgery
- ECOG Performance Status of 0 or 1
- Absolute neutrophil account ≥ 1.5 x109/l
- Platelet count ≥ 100 x 109/l
- Haemoglobin ≥90 g/l (previous transfusion is allowed)
- AST and ALT ≤ 2.5 x upper limit of normal (ULN). (At least one of ALT or AST MUST be performed)
- Creatinine clearance > 50 ml/min (calculated by Cockcroft Gault or Wright equation) or measured by EDTA
- Serum bilirubin ≤ 1.5 x ULN
- Signed and dated informed consent indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrolment.
- Age ≥ 18 years
- Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other trial procedures.
Exclusion Criteria:
- Non-adenocarcinoma histology of small bowel tumour which includes but is not confined to lymphoma, GIST, carcinoid or other neuroendocrine tumour, squamous carcinoma, melanoma or sarcoma.
- Previous neo-adjuvant chemo(radio)therapy for SBA
- Clinically significant cardiovascular disease (i.e. active or < 12 months since cerebrovascular accident, myocardial infarction, unstable angina, New York Heart Association [NYHA] grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, uncontrolled hypertension)
- Pregnancy/lactation or of child bearing potential and not using medically approved contraception. (Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential)
- Previous malignancy other than adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell carcinoma of the skin, unless there has been a disease free interval of at least 3 years and treatment was with curative intent
- Known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency
- Known untreated coeliac disease (may be enrolled if diet controlled), untreated chronic inflammatory bowel disease or other cause of malabsorption or intestinal obstruction
- Grade ≥ 2 peripheral neuropathy
- Administration of any investigational drug within 28 days or 5 halflives, whichever is longer, prior to receiving the first dose of trial treatment.
- Previous hypersensitivity to platinum salts
- Patients with clinically significant, active infections, or any other serious medical condition in which chemotherapy is contraindicated will be excluded
- Patients with untreated vitamin B12 deficiency are excluded from receiving folinic acid as part of their chemotherapy regimen. However, these patients may be eligible for treatment with capecitabine fluoropyrimidine therapy, where no folinic acid is administered as part of the treatment regimen
- Patients with clinically significant sensorineural hearing impairment are excluded from receiving oxaliplatin but will be eligible for the fluoropyrimidine monotherapy provided as a clinician's choice for patients in group 1 randomised to either observation or chemotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Group1 Arm A
Observation only
|
|
OTHER: Group 1 Arm B
Mono- or bichemotherapy: fluoropyrimidine with or without Oxaliplatin (choice by physician/patient or by randomisation)
|
Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine.
The choice of fluoropyrimidine must be specified prior to randomisation.
Other Names:
Bichemotherapy: Oxaliplatine combined with Fluoropyrimidine.
Other Names:
|
OTHER: Group 2 Arm C
Monochemotherapy: fluoropyrimidine
|
Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine.
The choice of fluoropyrimidine must be specified prior to randomisation.
Other Names:
|
OTHER: Group 2 ARM D
Bichemotherapy: fluoropyrimidine with oxaliplatin
|
Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine.
The choice of fluoropyrimidine must be specified prior to randomisation.
Other Names:
Bichemotherapy: Oxaliplatine combined with Fluoropyrimidine.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
efficacy assessed by the 3-year Disease-free survival
Time Frame: 3 years from randomisation
|
This is defined as time from randomisation to the first occurrence of the following events:
|
3 years from randomisation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
efficacy assessed by the overall survival
Time Frame: 5 years from randomisation
|
The patient's survival status is determined at each follow-up visit.
After the mandated clinic visits survival status data will come from responsible cancer centres, cancer registries and national databases and include long-term passive follow-up data.
|
5 years from randomisation
|
safety assessed by the toxicity of chemotherapy
Time Frame: until 1 month after treatment
|
Toxicity will be assessed using CTCAE version 4.0.
Only toxicities that are at least grade 2 will be recorded on the CRF
|
until 1 month after treatment
|
quality of life as assessed using the EORTC (European Organisation for Research and Treatment of Cancer) Quality of Life Questionnaire Core 30
Time Frame: until end of study, up to 5 years from randomisation
|
This will be completed at 9, 12, 18 and 24 months post randomisation for all arms of the trial.
Minimum and maximum values do not apply for this scale.
|
until end of study, up to 5 years from randomisation
|
quality of life as assessed using the EORTC (European Organisation for Research and Treatment of Cancer) Quality of Life Questionnaire Colo-Rectal module 29
Time Frame: until end of study, up to 5 years from randomisation
|
This will be completed at 9, 12, 18 and 24 months post randomisation for all arms of the trial.
Minimum and maximum values do not apply for this scale.
|
until end of study, up to 5 years from randomisation
|
quality of life as assessed using the EuroQol 5 dimension scale (EQ-5D)
Time Frame: until end of study, up to 5 years from randomisation
|
This will be completed at 9, 12, 18, 24, 30, 36, 48, 60 72 and 84 months post randomisation for all arms of the trial.
Minimum and maximum values do not apply for this scale.
|
until end of study, up to 5 years from randomisation
|
Exploratory: clinical applicability of the study results assessed by the translational research on blood and tissue
Time Frame: Will be collected at the end of study, up to 5 years from randomisation
|
The aim is to establish a biobank of SBA tissue and blood with complete and comprehensive trial quality follow-up data which may act as the foundation for many future collaborative research projects and for combined projects with other funded tissue collections.
|
Will be collected at the end of study, up to 5 years from randomisation
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marc Peeters, Prof, Coordinating Investigator
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BALLAD BELGIUM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Bowel Adenocarcinoma
-
Centre Hospitalier Universitaire DijonRecruitingLocally Advanced or Metastatic Small Bowel AdenocarcinomaFrance
-
Assistance Publique - Hôpitaux de ParisCentre Hospitalier Universitaire de Besancon; University of Paris 5 - Rene... and other collaboratorsCompletedSmall Bowel Adenocarcinoma
-
Copenhagen University Hospital at HerlevAarhus University Hospital; Rigshospitalet, Denmark; University of CopenhagenRecruitingSmall Bowel AdenocarcinomaDenmark
-
Zhe FanCompleted
-
Centre Hospitalier Universitaire DijonNot yet recruitingSmall Bowel Adenocarcinoma | Adjuvant Chemotherapy for SBAFrance
-
Asian Institute of Gastroenterology, IndiaCompletedSmall Bowel Disease | Small Bowel Ulcers | Capsule Endoscopy | Small Bowel Tumor
-
Odense University HospitalCompletedSimulation | Endoscopy | Education | Small Bowel Disease | Small Bowel Capsule EndoscopyDenmark
-
North-Western State Medical University named after...RecruitingSmall Bowel Obstruction | Small Bowel Obstruction Adhesion | Small-Bowel Obstruction Due to Volvulus | Hernia IncarceratedRussian Federation
-
Inonu UniversityUnknownSmall/Large Bowel
-
University of FloridaCompletedSmall Bowel VisualizationUnited States
Clinical Trials on Fluoropyrimidine
-
Tomoshi TsuchiyaCompleted
-
First People's Hospital of HangzhouCompletedCholangiocarcinomaChina
-
First People's Hospital of HangzhouXijing Hospital; Changhai Hospital; Cancer Institute and Hospital, Chinese Academy... and other collaboratorsCompleted
-
Stanford UniversityRecruitingBreast Cancer | Triple Negative Breast CancerUnited States
-
Henry Ford Health SystemCompletedPancreas Neoplasm Malignant ResectableUnited States
-
University of Alabama at BirminghamNational Cancer Institute (NCI)Terminated
-
Hospices Civils de LyonCompleted
-
Centre Hospitalier Universitaire DijonRecruiting
-
SanofiCompleted
-
Hoffmann-La RocheCompleted